Retatrutide (also referred to as LY3437943) is a novel triple agonist peptide that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This tri-receptor engagement profile distinguishes retatrutide from dual incretin agonists and positions it as a subject of significant interest in advanced metabolic research.
In preclinical and early clinical studies, retatrutide has demonstrated pronounced effects on energy homeostasis, appetite regulation, glycaemic control, and adipose tissue reduction. The glucagon receptor component is believed to contribute additional thermogenic and hepatic lipid-lowering effects beyond those seen with GLP-1/GIP dual agonists, making it a particularly compelling compound for researchers modelling obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and related cardiometabolic conditions.
Each vial contains 20mg of retatrutide supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis.
Store lyophilised peptide at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 72 hours. Avoid repeated freeze-thaw cycles.
Molecular Formula
C₁₄₉H₂₃₂N₄₀O₄₅
Molecular Weight
4963.5 g/mol
Purity
>98%
CAS Number
2381090-05-5
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity modelling, Type 2 diabetes research, NASH and hepatic lipid metabolism, Cardiometabolic studies, Energy homeostasis investigation
For research purposes only. Not for human use.
Reviews
There are no reviews yet.